|1.||Ohmiya, Harumi: 1 article (06/2006)|
|2.||Kubota, Tetsuro: 1 article (06/2006)|
|3.||Suto, Akihiko: 1 article (06/2006)|
|4.||Fukushima, Masakazu: 1 article (06/2006)|
|5.||Ikeda, Tadashi: 1 article (06/2006)|
|6.||Takeshita, Toshio: 1 article (06/2006)|
|7.||Kitajima, Masaki: 1 article (06/2006)|
|8.||Takashima, Shigemitsu: 1 article (01/2004)|
|9.||Sano, Muneaki: 1 article (01/2004)|
|10.||Saek, Toshiaki: 1 article (01/2004)|
11/01/1985 - "Because of the lack of a pattern in dihydrouracil dehydrogenase activity between tumors and normal tissues, the enzyme is not a good marker for tumorigenicity. "
11/01/1985 - "The activity of dihydrouracil dehydrogenase has been demonstrated in several human extrahepatic tissues and tumors. "
09/01/2000 - "Furthermore, the activities of UrdPase and orotate phosphoribosyltransferase (OPRTase, EC 220.127.116.11) were 192- and 2-fold higher, respectively, while that of dihydrouracil dehydrogenase (EC 18.104.22.168) was 1000-fold lower in the tumor than in the host liver. "
07/01/1996 - "This augmentation of an antitumor activity was supported by potent and prolonged inhibition of dihydrouracil dehydrogenase activity (5-FU degrading activities) in the liver of tumor-bearing rats after oral CDHP (0.2:0.8 molar ratio) and furthermore by elevation and over 12 h retention of 5-FU levels in the tumors following combined administration of FT and CDHP at a molar ratio of 1:0.4, respectively. "
06/01/2006 - "In vivo experiments were performed on breast cancer xenografts to examine whether the combination therapy with S-1, an oral dihydrouracil dehydrogenase (DPD) inhibitory fluoropyrimidine, plus docetaxel functions as an additive/synergistic modulator in tumor growth. "
|3.||Hepatocellular Carcinoma (Hepatoma)
|4.||Breast Neoplasms (Breast Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)